Cargando…
Efficacy and safety of GSK3772847 in participants with moderate-to-severe asthma with allergic fungal airway disease: A phase IIa randomized, multicenter, double-blind, sponsor-open, comparative trial
INTRODUCTION: Current treatments for allergic fungal airway disease are not specific for asthma and are associated with limited efficacy or safety concerns. This Phase IIa randomized, multicenter, double-blind, sponsor-open, comparative trial assessed the efficacy and safety of GSK3772847, an anti-i...
Autores principales: | Akinseye, Chika, Crim, Courtney, Newlands, Amy, Fairman, David |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9897512/ https://www.ncbi.nlm.nih.gov/pubmed/36735745 http://dx.doi.org/10.1371/journal.pone.0281205 |
Ejemplares similares
-
Safety, tolerability, and pharmacokinetics of a single ascending subcutaneous dose of GSK3772847 in healthy participants
por: Pefani, Eleni, et al.
Publicado: (2023) -
Demographic diversity of US-based participants in GSK-sponsored
interventional clinical trials
por: Reid, Michel M, et al.
Publicado: (2023) -
Allergic fungal airways disease (AFAD): an under-recognised asthma endotype
por: Pashley, Catherine H., et al.
Publicado: (2021) -
Epidemiology of Asthma and Allergic Airway Diseases
por: Devereux, Graham, et al.
Publicado: (2014) -
Nanoparticle uptake by airway phagocytes after fungal spore challenge in murine allergic asthma and chronic bronchitis
por: Geiser, Marianne, et al.
Publicado: (2014)